Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin in Friedreich Ataxia
NCT02705547Phase 1Completed
- Sponsor
- Children's Hospital of Philadelphia
- Start
- May 2016
- Primary completion
- Aug 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rosuvastatin in Friedreich ataxia (FA), sponsored by Children's Hospital of Philadelphia. Primary endpoint: Change in ApoA-1 serum protein levels at 12 weeks. Started May 2016; status: completed.
02
Drugs
rosuvastatin
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on NCT02705547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02705547.